CDXC:NSD-ChromaDex Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.89

Change

+0.04 (+0.82)%

Market Cap

USD 0.30B

Volume

0.15M

Average Target Price

USD 8.33 (+70.42%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.74 (-3.01%)

USD62.38B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.45 (+0.64%)

USD58.99B 22.23 17.39
REGN Regeneron Pharmaceuticals, Inc

-6.39 (-1.28%)

USD53.23B 18.28 14.53
SGEN Seagen Inc

-0.93 (-0.52%)

USD32.25B 68.04 62.62
BNTX BioNTech SE

+1.32 (+1.11%)

USD29.16B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

-0.55 (-0.45%)

USD26.49B 28.09 26.92
RPRX Royalty Pharma plc

+0.68 (+1.61%)

USD26.44B 22.60 9.98
GMAB Genmab A/S

+0.10 (+0.26%)

USD24.77B 26.59 2.61
BGNE BeiGene, Ltd

+1.57 (+0.71%)

USD20.63B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CDXC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.46% 55% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.46% 55% F 62% D-
Trailing 12 Months  
Capital Gain 27.84% 55% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.84% 55% F 68% D+
Trailing 5 Years  
Capital Gain 25.38% 70% C- 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.38% 70% C- 48% F
Average Annual (5 Year Horizon)  
Capital Gain 7.76% N/A N/A 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.76% N/A N/A 56% F
Risk Return Profile  
Volatility (Standard Deviation) 43.67% N/A N/A 27% F
Risk Adjusted Return 17.76% N/A N/A 44% F
Market Capitalization 0.30B 50% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 15.41 9% F 8% F
Price / Cash Flow Ratio -14.66 72% C- 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -97.28% 31% F 12% F
Return on Invested Capital -131.45% 17% F 6% F
Return on Assets -35.12% 35% F 10% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 9.49 25% F 13% F
Short Percent 4.65% 61% D- 40% F
Beta 1.52 49% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector